

AmÃ©lie Marsot

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6847255/publications.pdf>

Version: 2024-02-01

31
papers

676
citations

758635

12
h-index

580395

25
g-index

32
all docs

32
docs citations

32
times ranked

1014
citing authors

#	ARTICLE	IF	CITATIONS
1	An Update on Population Pharmacokinetic Analyses of Vancomycin, Part II: In Pediatric Patients. <i>Clinical Pharmacokinetics</i> , 2022, 61, 47-70.	1.6	12
2	Consideration of heightâ€based tobramycin dosing regimens for the treatment of adult cystic fibrosis pulmonary exacerbations. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2246-2255.	1.1	4
3	Using a Validated Population Pharmacokinetic Model for Dosing Recommendations of Continuous Infusion Piperacillin for Critically Ill Adult Patients. <i>Clinical Pharmacokinetics</i> , 2022, 61, 895-906.	1.6	4
4	Validation of the Augmented Renal Clearance in Trauma Intensive Care scoring system for augmented renal clearance prediction in a trauma subgroup of a mixed <scp>ICU</scp> population. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 1517-1524.	0.7	2
5	Model Re-Estimation: An Alternative for Poor Predictive Performance during External Evaluations? Example of Gentamicin in Critically Ill Patients. <i>Pharmaceutics</i> , 2022, 14, 1426.	2.0	3
6	Antibiotics in Adult Cystic Fibrosis Patients: A Review of Population Pharmacokinetic Analyses. <i>Clinical Pharmacokinetics</i> , 2021, 60, 447-470.	1.6	5
7	Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses. <i>Clinical Pharmacokinetics</i> , 2021, 60, 855-875.	1.6	16
8	Aminoglycosides in the Intensive Care Unit: What Is New in Population PK Modeling?. <i>Antibiotics</i> , 2021, 10, 507.	1.5	13
9	Population pharmacokinetic models of first choice beta-lactam antibiotics for severe infections treatment: What antibiotic regimen to prescribe in children?. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2020, 23, 470-485.	0.9	5
10	External evaluation of population pharmacokinetic models for continuous administration of meropenem in critically ill adult patients. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1281-1289.	0.8	13
11	Amikacin nomogram for treatment of adult cystic fibrosis exacerbations based on an external evaluation of a population pharmacokinetic model. <i>Pediatric Pulmonology</i> , 2020, 55, 1154-1160.	1.0	6
12	An Update on Population Pharmacokinetic Analyses of Vancomycin, Part I: In Adults. <i>Clinical Pharmacokinetics</i> , 2020, 59, 671-698.	1.6	47
13	Evaluation of current dosing guidance for oral rifampicin treatment in adult patients with osteoarticular infections. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2319-2324.	1.1	3
14	What is the recommended amikacin dosing for cystic fibrosis patients with acute pulmonary exacerbations?. <i>Pediatric Pulmonology</i> , 2019, 54, 1652-1653.	1.0	1
15	Pharmacokinetic Variability in Pediatrics and Intensive Care: Toward a Personalized Dosing Approach. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2018, 21, 354-362.	0.9	14
16	Vancomycin in Pediatric Patients with Solid or Hematological Malignant Disease: Predictive Performance of a Population Pharmacokinetic Model and New Optimized Dosing Regimens. <i>Paediatric Drugs</i> , 2018, 20, 375-381.	1.3	4
17	Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies. <i>Clinical Pharmacokinetics</i> , 2017, 56, 127-138.	1.6	56
18	Phenobarbital in intensive care unit pediatric population: predictive performances of population pharmacokinetic model. <i>Fundamental and Clinical Pharmacology</i> , 2017, 31, 558-566.	1.0	9

#	ARTICLE	IF	CITATIONS
19	Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1039-1047.	1.1	12
20	Levodopa in Parkinson's Disease: A Review of Population Pharmacokinetics/Pharmacodynamics Analysis. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2017, 20, 226.	0.9	13
21	Population Pharmacokinetics of High-Dose Oxazepam in Alcohol-Dependent Patients. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 253-258.	1.0	3
22	Pediatric Patients With Solid or Hematological Tumor Disease: Vancomycin Population Pharmacokinetics and Dosage Optimization. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 559-566.	1.0	25
23	Nicotine and Cotinine Levels With Electronic Cigarette. <i>International Journal of Toxicology</i> , 2016, 35, 179-185.	0.6	90
24	Population pharmacokinetics of methadone hydrochloride after a single intramuscular administration in adult Japanese sika deer (<i>Cervus nippon nippon</i>). <i>Veterinary Anaesthesia and Analgesia</i> , 2015, 42, 165-172.	0.3	2
25	Population pharmacokinetics of ertapenem in juvenile and old rats. <i>Fundamental and Clinical Pharmacology</i> , 2014, 28, 144-150.	1.0	4
26	High Variability in the Exposure of Baclofen in Alcohol-Dependent Patients. <i>Alcoholism: Clinical and Experimental Research</i> , 2014, 38, 316-321.	1.4	35
27	Pharmacokinetics and absolute bioavailability of phenobarbital in neonates and young infants, a population pharmacokinetic modelling approach. <i>Fundamental and Clinical Pharmacology</i> , 2014, 28, 465-471.	1.0	26
28	Interaction of thiopental with esomeprazole in critically ill patients. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1667-1672.	0.8	6
29	Vancomycin: Predictive Performance of a Population Pharmacokinetic Model and Optimal Dose in Neonates and Young Infants. <i>Clinical Pharmacology in Drug Development</i> , 2012, 1, 144-151.	0.8	8
30	Population Pharmacokinetic Analysis during the First 2 Years of Life. <i>Clinical Pharmacokinetics</i> , 2012, 51, 787-798.	1.6	38
31	Vancomycin. <i>Clinical Pharmacokinetics</i> , 2012, 51, 1-13.	1.6	194